NEW YORK, Nov. 16, 2021 /CNW/ — Mind Medicine (MindMed) Inc. (NASDAQ: MNMD; NEO: MMED; DE: MMQ; the “Company”), a leading biotech company developing psychedelic-inspired therapies, is pleased to announce it has launched recruitment for a randomized placebo-controlled study evaluating the effects of daytime and evening administration of repeated low doses of LSD (the “LSD Study”).


Previous articleDiscussions With FDA Provide Guidance for Phase IIb Clinical Trial Design for DMT-Assisted Therapy for Major Depressive Disorder
Next articlePT273 – Erica Rex – Clinical Trials and Spontaneous Mystical Experiences